Renzapride

Drugbox
IUPAC_name = 4-amino-N- [(5S,6S)-1-azabicyclo [3.3.1] nonan-6-yl] -5-chloro-2-methoxybenzamide


CAS_number = 109872-41-5
ATC_prefix =
ATC_suffix =
PubChem = 3086547
DrugBank =
C=16|H=22|Cl=1|N=3|O=2
molecular_weight = 323.818 g/mol
smiles = COC1=CC(=C(C=C1C(=O)N [C@H] 2CCN3CCC [C@H] 2C3)Cl)N
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Renzapride is a full serotonin 5-HT₄ receptor agonist, partial serotonin 5-HT₃ and 5-HT_2b receptor antagonist [Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", "Clin. Gastroent. and Hepatology"; 2:895-904] .

Clinical Uses

Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom.

As of 23rd April 2008, Alizyme has ceased all development of this drug, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.

References